

ML-IAP (h): 293T Lysate: sc-159337

BACKGROUND

Inhibitor of apoptosis proteins (IAPs) contain conserved, unique N-terminal baculovirus IAP repeats (BIRs) and usually a C-terminal RING finger domain. Immunoprecipitation and Western blot analysis indicate that ML-IAP, also known as melanoma inhibitor of apoptosis protein, kidney inhibitor of apoptosis protein (KIAP), livin or BIRC7, binds to caspase-3, -7 and -9, but only inhibits caspase-9. Additionally, ML-IAP physically interacts with Smac through its BIR domain in a highly specific manner. The gene which encodes ML-IAP maps to human chromosome 20q13.33. There is controversy regarding the localization of this protein and its involvement in apoptosis, but it has been suggested that ML-IAP may play a complex role in the regulation of apoptosis.

REFERENCES

1. Vucic, D., Stennicke, H.R., Pisabarro, M.T., Salvesen, G.S. and Dixit, V.M. 2000. ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. *Curr. Biol.* 10: 1359-1366.
2. Lin, J.H., Deng, G., Huang, Q. and Morser, J. 2000. KIAP, a novel member of the inhibitor of apoptosis protein family. *Biochem. Biophys. Res. Commun.* 279: 820-831.
3. Kasof, G.M. and Gomes B.C. 2001. Livin, a novel inhibitor of apoptosis protein family member. *J. Biol. Chem.* 276: 3238-3246.
4. Ashhab, Y., Alian, A., Polliack, A., Panet, A. and Ben Yehuda, D. 2001. Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. *FEBS Lett.* 495: 56-60.
5. Online Mendelian Inheritance in Man, OMIM™. 2001. Johns Hopkins University, Baltimore, MD. MIM Number: 605737. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
6. Vucic, D., Deshayes, K., Ackerly, H., Pisabarro, M.T., Kadkhodayan, S., Fairbrother, W.J. and Dixit, V.M. 2002. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). *J. Biol. Chem.* 277: 12275-12279.
7. Franklin, M.C., Kadkhodayan, S., Ackerly, H., Alexandru, D., Distefano, M.D., Elliott, L.O., Flygare, J.A., Mausisa, G., Okawa, D.C., Ong, D., Vucic, D., Deshayes, K. and Fairbrother, W.J. 2003. Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). *Biochemistry* 42: 8223-8231.
8. Andersen, M.H., Becker, J.C. and Straten, P. 2004. Identification of an HLA-A3-restricted cytotoxic T lymphocyte (CTL) epitope from ML-IAP. *J. Invest. Dermatol.* 122: 1336-1337.
9. Vucic, D., Franklin, M.C., Wallweber, H.J., Das, K., Eckelman, B.P., Shin, H., Elliott, L.O., Kadkhodayan, S., Deshayes, K., Salvesen, G.S. and Fairbrother, W.J. 2004. Engineering ML-IAP to produce an extraordinarily potent caspase 9 inhibitor: implications for Smac-dependent anti-apoptotic activity of ML-IAP. *Biochem. J.* 385: 11-20.

STORAGE

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

CHROMOSOMAL LOCATION

Genetic locus: BIRC7 (human) mapping to 20q13.33.

PRODUCT

ML-IAP (h): 293T Lysate represents a lysate of human ML-IAP transfected 293T cells and is provided as 100 µg protein in 200 µl SDS-PAGE buffer.

APPLICATIONS

ML-IAP (h): 293T Lysate is suitable as a Western Blotting positive control for human reactive ML-IAP antibodies. Recommended use: 10-20 µl per lane.

Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.